Tags: dealtalk, Novartis, Roche
Biotech rumor mill has it that since Roche Share Discount Widens on Bet Novartis to Sell Stake for $14.1 billion. Read the full story
Tags: Parkinson's Disease, pharma deals, pharma licensing, Roche
Roche and Prothena have entered in a pharma licensing deal for Parkinson’s disease for $600 million. Read the full story
Tags: cancer, licensing, pharma deals, pharma licensing, Roche
Roche and Molecular Partners have entered into a research collaboration and licensing agreement for $1.169 billion. Read the full story
Tags: big biotech, big pharma, deal analysis, industry trends, Roche
This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in November 2013 Read the full story
Tags: big pharma, HIV, pharma licensing, Roche
Viriom enters into a pharma licensing agreement with Roche for an innovative drug for HIV/AIDS.
Read the full story
Tags: cancer, co-development, pharma alliances, Roche, vaccines
immatics biotechnologies forms a pharma alliances with Roche for a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics for $1.017billion.
Tags: antibiotics, big biotech, big pharma, infective, pharma licensing, Roche
Polyphor and Roche have entered into an exclusive worldwide pharma licensing deal to develop and commercialize Polyphor’s investigational macrocycle antibiotic, POL7080.
Tags: dealtalk, M&A, partnering, Roche
Swiss drugmaker Roche Holding AG would not exclude a move into treatments for rare diseases, its CEO said on Wednesday, even if this represented very small numbers of patients Read the full story
Tags: big pharma, pharma alliances, Roche
Samsung BioLogics announced that Samsung BioLogics and F. Hoffmann-La Roche, a big pharma, pharma alliances for a long term strategic manufacturing agreement. Read the full story
Tags: Amgen, big biotech, big pharma, Roche
Amgen biopharma partners by acquiring Roche‘s rights to the neutropenia drugs filgrastim and pegfilgrastim, effective January 1, 2014 Read the full story
Home | Reports | Services | Insight | News | Events | Scorecard | About us | Terms & conditions | Subscribe | Contact us
© 2013 Wildwood Ventures Ltd.